You just read:

Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

News provided by

Novo Nordisk

Jun 11, 2019, 14:45 ET